✦ LIBER ✦

An overview of phase II studies of docetaxel in patients with metastatic breast cancer

✍ Scribed by E.A. Eisenhauer; M. Trudeau

Book ID: 116166471
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 331 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)00359-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Weekly Docetaxel and C

Phase II Study of Weekly Docetaxel and Capecitabine in Patients with Metastatic Breast Cancer

✍ Ewa Mrozek; Bhuvaneswari Ramaswamy; Donn Young; Chris A. Rhoades; Kari Kendra; J 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 111 KB

A phase II study of weekly docetaxel in

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

✍ Hugo E. R. Ford; Yoon-Sim Yap; David W. Miles; Andreas Makris; Marcia Hall; Liz 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 311 KB

Irinotecan combined with docetaxel in pr

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study

✍ G. P. Stathopoulos; D. Tsavdaridis; N. A. Malamos; S. K. Rigatos; Ch. Kosmas; N. 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 194 KB

Phase II Study of Weekly Docetaxel Alone

Phase II Study of Weekly Docetaxel Alone or in Combination with Trastuzumab in Patients with Metastatic Breast Cancer

✍ Joshua P. Raff; Lakshmi Rajdev; Umekalsoom Malik; Yelena Novik; Jane M. Manalo; 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 126 KB

Phase II multicentre study of docetaxel

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer

✍ Lortholary, A; Delozier, T; Monnier, A; Bourgeois, H; Bougnoux, P; Tubiana-Mathi 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi